Access to the PPM Journal and newsletters is FREE for clinicians.

In The Pipeline: New Chronic Back Pain Approach—Surgery And Stimulation

July 10, 2019
Founded in 2015, SynerFuse will begin Phase I testing starting in 2019.

A PPM Brief

Minneapolis-based startup SynerFuse has secured $2.64 million in equity financing to help support development of its low back pain device, according to a news report1 SynerFuse’s device combines two FDA-approved technologies, fusion surgery and a neuromodulation implant, to treat long-term post-surgery low back pain. According to its website, the device works to improves spine implants by embedding active neuromodulation therapy simultaneously when surgeons are performing fusion back surgery. The incorporation of sensors will also allow physicians to optimize the system.

According to the news report, the company aims to use the funds to support their first clinical trial of the device. Phase I testing is upcoming in 2019 with 20 patients and is expected to run for one full year. If successful, Synerfuse aims to pursue further clinical trials.

SynerFuse has secured venture funding for its opioid-free device for chronic back pain. (Source: 123RF)

According to the SynerFuse website, more than 50% of patients who undergo spinal fusion surgery require long-term pain management therapies, relying often on opioids for relief. SynerFuse’s approach will aim to both reduce the incidence of residual pain and reduce the use of opioids. The company website suggests that through their combined approach, “patients will receive synergistic and more robust pain relief than either therapy could provide alone.”

The company was founded by Nazmi Peyman, MD, who also serves as director. Dr. Peyman Nazmi is board-certified in pain management and anesthesiology and completed his residency and fellowship training at the Albert Einstein College of Medicine/Montefiore Medical Center of New York in 1997. He is a graduate of the Medical University of Pecs in Hungary and is a member of the Spine Intervention Society (SIS) and American Society of Interventional Pain Physicians (ASIPP). The company’s co-founders are Justin Zenanko, CFO (representing CEO), and Gregory F. Molnar, PhD, associate professor in the Department of Neurology and director of the Deep Brain Stimulation Research Program at the University of Minnesota (representing CSO).

Last updated on: July 30, 2019
Continue Reading:
Prospective Study of a Lumbar Back Brace In an Interventional Pain Practice
close X